Luca Malorni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4453231/publications.pdf

Version: 2024-02-01

92 papers	2,475 citations	236833 25 h-index	206029 48 g-index
93 all docs	93 docs citations	93 times ranked	3945 citing authors

#	Article	IF	Citations
1	A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer. Clinical Cancer Research, 2005, 11, 4741-4748.	3.2	312
2	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	3.0	218
3	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Research and Treatment, 2012, 136, 795-804.	1.1	175
4	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Molecular Oncology, 2015, 9, 749-757.	2.1	146
5	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 541-552.	12.5	121
6	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research, 2008, 68, 7493-7501.	0.4	120
7	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666.	1.3	113
8	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget, 2016, 7, 68012-68022.	0.8	110
9	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	2.3	78
10	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Annals of Oncology, 2018, 29, 1748-1754.	0.6	76
11	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308.	0.8	53
12	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. Cancers, 2019, 11, 1894.	1.7	53
13	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	3.2	49
14	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene, 2003, 22, 246-255.	2.6	46
15	New approaches for improving outcomes in breast cancer in Europe. Breast, 2015, 24, 321-330.	0.9	42
16	Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Annals of Oncology, 2005, 16, iv7-iv13.	0.6	41
17	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139.	3.2	40
18	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research, 2016, 14, 470-481.	1.5	39

#	Article	IF	Citations
19	Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget, 2018, 9, 16389-16399.	0.8	37
20	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Current Opinion in Oncology, 2014, 26, 568-575.	1.1	33
21	Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. Biomolecules, 2020, 10, 1677.	1.8	31
22	RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. Oncogene, 2005, 24, 6303-6313.	2.6	30
23	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptorâ€“positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer, 2019, 114, 55-66.	1.3	30
24	Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?. Cancers, 2014, 6, 684-707.	1.7	28
25	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Medicine, 2015, 13, 46.	2.3	27
26	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. Clinical Cancer Research, 2020, 26, 2783-2788.	3.2	27
27	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136.	3.4	25
28	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews, 2019, 74, 29-34.	3.4	23
29	Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells, 2020, 9, 668.	1.8	23
30	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 4687.	1.8	23
31	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. BMC Genomics, 2018, 19, 960.	1.2	22
32	Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Research and Treatment, 2010, 123, 651-660.	1.1	21
33	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5755-5764.	3.2	20
34	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research, 2019, 21, 71.	2.2	19
35	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 329-341.	1.1	17
36	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, 2009, 28, 135.	3.5	16

#	Article	IF	Citations
37	The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	1.4	14
38	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Research, 2021, 23, 38.	2.2	14
39	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers, 2021, 13, 2762.	1.7	14
40	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2â^') metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	0.8	14
41	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	1.1	12
42	Polyendocrine Treatment in Estrogen Receptorâ€"Positive Breast Cancer: A â€œFACTâ€•Yet to Be Proven. Journal of Clinical Oncology, 2012, 30, 1897-1900.	0.8	10
43	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. Breast, 2018, 38, 144-149.	0.9	10
44	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. Npj Breast Cancer, 2022, 8, 24.	2.3	9
45	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. Cancers, 2021, 13, 2640.	1.7	8
46	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 2022, 164, 39-51.	1.3	8
47	Charting differentially methylated regions in cancer with Rocker-meth. Communications Biology, 2021, 4, 1249.	2.0	7
48	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 3-8.	1.8	5
49	AhR (Aryl Hydrocarbon Receptor) Polymorphisms: A Possible Role in TCDD (Dioxins)-AhR Binding and Carcinogenesis. International Journal of Biology, 2014, 6, .	0.1	5
50	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	5
51	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Research, 2018, 38, 4839-4845.	0.5	5
52	Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046). , 2020, , .		5
53	Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial. Cancer Research, 2022, 82, GS3-07-GS3-07.	0.4	5
54	Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. British Journal of Cancer, 2020, 123, 176-177.	2.9	4

#	Article	IF	Citations
55	Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial. , 2021, , .		4
56	A multifactorial â€˜Consensus Signatureâ€™ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. Npj Breast Cancer, 2015, 1, 15003.	2.3	3
57	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	1.4	3
58	292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial. Annals of Oncology, 2021, 32, S492.	0.6	3
59	Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse) Tj ETQq1 1 0.784314 rgBT /Overlock 10		3
60	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. Biomarkers in Medicine, 2020, 14, 495-498.	0.6	3
61	Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse. Applied Sciences (Switzerland), 2021, 11, 11120.	1.3	3
62	Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptorâ€“positive (HR+), human epidermal growth factor 2â€“negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.. Journal of Clinical Oncology, 2022, 40, 1012-1012.	0.8	3
63	Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		2
64	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 3-8.	1.8	2
65	The continued evidence from overviews: What is the clinical utility?. Breast, 2013, 22, S8-S11.	0.9	1
66	Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. Annals of Oncology, 2014, 25, i8.	0.6	1
67	Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer. Breast Care, 2017, 12, 288-289.	0.8	1
68	11P BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC). Annals of Oncology, 2020, 31, S20.	0.6	1
69	Triple-negative breast cancers: Biomarkers and outcomes.. Journal of Clinical Oncology, 2010, 28, 10621-10621.	0.8	1
70	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 1025-1025.	0.8	1
71	Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.. Journal of Clinical Oncology, 2018, 36, 12031-12031.	0.8	1
72	Palbociclib added to ongoing endocrine therapy for hormone receptorâ€‘positive HER2â€‘negative metastatic breast cancer: A case report series. Molecular and Clinical Oncology, 2020, 12, 456-460.	0.4	1

#	Article	IF	Citations
73	PCN138 HEALTH-CARE COSTS ASSOCIATED WITH BREAST CANCER MANAGEMENT. Value in Health, 2010, 13, A278.	0.1	0
74	S07 Overcoming resistance to endocrine therapies: Multiple interventions to reach the goal. Breast, 2011, 20, S4.	0.9	0
75	Introduction: Luminal A and B: How Curable are they?. Annals of Oncology, 2012, 23, ix27.	0.6	0
76	Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC). Annals of Oncology, 2015, 26, iii15.	0.6	0
77	Targeting the CDK4/6 Pathway in Breast Cancer. , 2017, , 807-817.		0
78	Metabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD). Annals of Oncology, 2017, 28, i17.	0.6	0
79	Abstract OT-28-02: Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive / HER2-positive breast cancer - The TOUCH trial. , 2021, , .		0
80	Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.. , 2009, , .		0
81	P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.. , 2011, , .		0
82	Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. , 2015, , .		0
83	Abstract P1-09-13: A RB-1 loss-of-function gene-signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/ER+ breast cancer patients. , 2017, , .		0
84	Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib. , 2017, , .		0
85	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	0.8	0
86	Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?. Oncotarget, 2018, 9, 34031-34032.	0.8	0
87	Abstract 2471: Pan-cancer catalog of Differentially Methylated Regions by Rocker-meth, a new computational method. , 2019, , .		0
88	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		0
89	Abstract P4-04-07: A DNA-methylation signature to predict resistance to the CDK4/6 inhibitor palbociclib. , 2020, , .		0
90	Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , .		0

#	Article	IF	Citations
91	Abstract P5-13-13: PIK3CA mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and HER2 negative metastatic breast cancer. Cancer Research, 2022, 82, P5-13-13-P5-13-13.	0.4	0
92	Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , .		0